课题基金 / 基金详情

SAFETY & EFFICACY OF LANREOTIDE (IPSTYL) IN ACROMEGALICS

SAFETY & EFFICACY OF LANREOTIDE (IPSTYL) IN ACROMEGALICS
安全
批准号：
6264604
负责人：
DAVID L KLEINBERG
金额：
$2.1万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6264604
关键词：
acromegaly clinical research drug adverse effect drug screening /evaluation endocrine disorder chemotherapy hormone therapy human subject human therapy evaluation insulinlike growth factor neoplasm /cancer chemotherapy peptide hormone analog skeletal disorder chemotherapy somatostatin somatotropin

项目摘要

项目成果

DAVID L KLEINBERG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The primary objective of this Phase II/III open label trial is to investigate the safety and efficacy of lanreotide (IPSTYL), a synthetic analog of somatostatin with a prolonged half-life, in normalizing GH and IGF-1 levels. Secondary objectives are to investigate the safety and efficacy of IPSTYL in terms of tumor response, symptomatology, adverse events and proportion of patients in whom GH have been reduced to near normal levels. Lancreotide is given as a single injection every 10-14 days. This study is similar to 802 except these patients have acromegaly not cured by surgery.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SURGICAL DEBULKING PLUS OCTREOTIDE VERSUS OCTREOTIDE ALONE IN ACROMEGALY
PREVALENCE OF GROWTH HORMONE DEFICIENCY & RANGES OF IGF-1 IN NORMAL ELDERLY
PREVALENCE OF GROWTH HORMONE DEFICIENCY & RANGES OF IGF-1 IN NORMAL ELDERLY
Prevalence of Growth Hormone Deficiency & Ranges of IGF-1 in Normal Elderly
海外基金